Clinically, they are routinely used as therapeutic agents such as fenofibrate, a PPARα agonist, for hyperlipidaemia, as well as pioglitazone, a PPARγ agonist for diabetes [19, 20]. Here, PPARA is linked to hyperlipidemia.